by HAEMATO AG | May 18, 2018 | Investor News
HAEMATO AG is a listed pharmaceutical company focusing on the growth markets of high-priced special pharmaceuticals from the indication areas oncology and HIV as well as in the areas of rheumatism, neurology and cardiovascular diseases. In addition, the company... 
by HAEMATO AG | May 7, 2018 | Investor News
HAEMATO AG is a listed pharmaceutical company with a focus on the growth markets of special pharmaceuticals, primarily in the high-priced indication areas of oncology and HIV as well as rheumatism, neurology and cardiovascular diseases. HAEMATO AG had a successful... 
by HAEMATO AG | Mar 29, 2018 | Investor News
2017: According to the preliminary IFRS results, Haemato AG increased its sales by 5.2% to EUR 289.9 million. In 2017, HAEMATO AG, Berlin (ISIN: DE0006190705), achieved an IFRS group turnover of €289,9m (previous year: €275.6m), an operating result (EBIT) of €9.4... 
by HAEMATO AG | Nov 30, 2017 | Investor News
HAEMATO AG is a listed pharmaceutical company with focus on the growth markets of high-end specialty pharmaceuticals in the indication groups of oncology and HIV as well as in the areas of rheumatism, neurology and cardiovascular diseases. In addition, the in-house... 
by HAEMATO AG | Aug 31, 2017 | Investor News
HAEMATO AG is a listed pharmaceutical company focusing on the growth markets of patent-free and patent-protected drugs primarily in the high-price indicative areas of oncology and HIV as well as in the areas of rheumatism, neurology and cardiac, circulatory diseases....
